New Page 1
By: AllPennyStocks.com
As the H1N1 flu pandemic occupies more and more of the world’s consciousness as
the year comes to an end, more of the spotlight is focused on companies that can
reduce the risk of further medical trouble as the result of unsafe needles
administering the vaccine against the potentially fatal strain. One such
company, headquartered in Charleston, South Carolina, announced in mid-December
it’s going ahead full-tilt with taking its flagship product into full mass
production mode.
Revolutions Medical Corporation (OTCBB: RMCP) makes the RevVac safety syringe,
as well as other products such as the RevColor, RevDisplay and Rev3D MRI
Technology, and has ramped up manufacture of the RevVac syringe, which not too
long ago got the okay from the U.S. Food and Drug Administration (FDA).
RMCP is committed to developing and distributing consistently new products and
tools to the medical industry, whether internally or through acquisitions. Its
goals are to make health care safer and less expensive by reducing risks and
cutting time and expenses.
For reasons discussed above, the world market for safety-engineered medical
devices (SEMDs) is projected to exceed two billion this year and is forecasted
to maintain a 20% annual growth rate in the near term. The other tools in RMCP’s
holster will enhance the physician's diagnostic confidence in an industry that
is growing at 10% - 15% (more than 25 million procedures) per year with a
worldwide market potential for these tools that exceeds $3.5 billion U.S.
Earlier this month, the company exhibited its MRI software products at this
week's Radiology Society of North America (RSNA) annual meeting, coming away
with rave reviews. A number of these contacts could play an important role in
the Company's ongoing efforts to validate clinically specific applications of
its MRI tools prior to the 2010 commercial launch.
Timely hot topics at the show included MRI analysis in breast disease, and brain
abnormalities such as the depth of injury in concussion (as reported by the NFL)
led to discussions as to how the unique MRI color software would aid in image
analysis, thereby enhancing diagnostic confidence in an entirely different way.
By hitting its primary milestone, RevMed satisfies its previously announced
commitment to begin production in this year’s last fiscal quarter. The company
also stays on pace to meet its second-quarter sales launch goal in fiscal 2010
and $14.8-million revenue projection for the coming year.
The stock was an anomaly in March, sustaining its 52-week peak when pretty much
everyone else in the market was floundering. The price hit 71 cents a share on
March 30, only a matter of week after plumbing the depths at 14 cents in
mid-February. The news that the company was stepping up syringe production sent
the stock zigzaging, and at last check was down to $0.37, at a significant
discount compared to the positive news announced.
About AllPennyStocks.com:
AllPennyStocks.com is a website devoted to Canadian and American Stocks and
Penny Stocks. Some features in the website include quotes, news and charts. The
site also offers weekly write-ups of financial news, weekly penny stocks to
watch, daily top 50 penny stocks info, technical analysis, a portfolio manager,
a section for visitors to input their own penny stock picks, as well as an
elaborate amount of information for beginning investors. Visitors can sign up to
the AllPennyStocks.com mailing list to receive more penny stock articles, stock
profiles and more. AllPennyStocks.com is a well developed and recognized
financial site among the investment community.
Disclosure:
AllPennyStocks.com has been compensated twenty two thousand five hundred dollars
by the company for its efforts in presenting the RMCP profile on its web site
and distributing it to its database of subscribers as well as other services. A
full disclaimer on RMCP can be found at:
http://www.allpennystocks.com/aps_us/company_spotlights/archives/rmcp.asp.
